Exert from AZ RNS this morning11 Nov 2022 07:08
"In the US, lung cancer is the second most commonly diagnosed cancer, with more than 236,000 patients expected to be diagnosed in 2022.1 For patients with metastatic NSCLC, prognosis is particularly poor, as only approximately 8% will live beyond five years after diagnosis.2"
If CIZ has a reliable test to detect lung cancer early then the SP will multiply bigly imo. Astra Zeneca could CIZ for pennies and then offer US customers/health insurers an early test and an effective chemo treatment mix.